Antibodies to angiogenesis inhibiting domains of CD148
AssigneeAmgen Inc.
InventorsJames F. Smothers, William C. Fanslow, III, Revital Kariv
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods relating to anti-CD148 receptor antibodies. Methods provided include inhibiting angiogenesis and, thereby, vascularization of solid tumors in human patients. The present invention also provides compositions and methods for in vivo imaging of tumors expressing CD148. Compositions of the invention include: anti-CD148 antibodies, antigen binding regions of anti-CD148 antibodies, polynucleotides encoding anti-CD 148 antibodies or binding regions thereof, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions is also provided.
Claims31
An isolated antibody or an antigen binding region thereof, comprising a polypeptide sequence having at least 90% sequence identity to a variable chain sequence selected from the group consisting of:
- SEQ ID NOS:
- 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32, and wherein said antibody or antigen binding region specifically binds to the extracellular domain of human CD148.
An isolated antibody or isolated antigen binding region thereof comprising at least one complementarity determining regions (CDRs), wherein said CDRs are localized at and inclusive of residues:
- a) 31-35, 50-66, or, 99-109 of SEQ ID NO:
- [2];
- b) 23-36, 52-58, or, 91-101 of SEQ ID NO:
- [4]
- c) 31-35, 56-66, or, 99-111 of SEQ ID NO:
- [6]
- d) 24-34, 50-56, or, 89-97 of SEQ ID NO:
- [8];
- e) 31-35, 50-66, or, 99-107 of SEQ ID NO:
- [10];
- f) 24-34, 50-66, or, 89-97 of SEQ ID NO:
- [1,2];
- g) 31-35, 50-66, or, 99-112 of SEQ ID NO:
- [1,4];
- h) 23-33, 49-55, or, 88-98 of SEQ ID NO:
- [1,6];
- i) 31-35, 50-66, or, 99-114 of SEQ ID NO:
- [1,8];
- j) 23-33, 49-55, or, 88-98 of SEQ ID NO:
- [20];
- k) 31-35, 50-66, or, 99-107 of SEQ ID NO:
- [22];
- l) 23-35, 51-57, or, 90-101 of SEQ ID NO:
- [24];
- m) 31-35, 50-66, or, 99-107 of SEQ ID NO:
- [26];
- n) 23-35, 51-57, or, 90-100 of SEQ ID NO:
- [28];
- o) 31-35, 50-66, or, 99-112 of SEQ ID NO:
- [30];
- or,
- p) 23-35, 51-57, or, 90-100 of SEQ ID NO:
- [32];
- and,
- wherein said isolated antibody or antigen binding region specifically binds to the extracellular domain of human CD148.
Dependencies are inferred from the claim text.